This consensus report from four professional transplant organizations establishes recommendations on the role of high-dose therapy with autologous or allogeneic HCT in multiple myeloma patients relapsing after primary therapy. Several consensus statements were issued in the report, with the primary recommendation for salvage autologous HCT being: In transplant-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard. For allogeneic HCT, the primary recommendation is: Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (i.e., cytogenetics, extramedullary disease, plasma cell leukemia or high LDH).
Giralt S, et al. Biol Blood Marrow Transplant